Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY19.92 CNY
Change Today +0.35 / 1.79%
Volume 6.9M
600513 On Other Exchanges
As of 3:05 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

jiangsu lianhuan pharmaceu-a (600513) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/14 - CNY21.20
52 Week Low
04/28/14 - CNY10.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JIANGSU LIANHUAN PHARMACEU-A (600513)

Related News

No related news articles were found.

jiangsu lianhuan pharmaceu-a (600513) Related Businessweek News

No Related Businessweek News Found

jiangsu lianhuan pharmaceu-a (600513) Details

Jiangsu Lianhuan Pharmaceutical Co., Ltd. engages in the research, development, manufacture, sale, and export of pharmaceutical products in China. The company also offers chemical preparations and organic intermediates. Its primary products include steroid hormone, antibiotic, antihistamine, cardiovascular, anti-allergic, and urological surgery drugs, such as felodipine, ebastine, terfenadine, cetirizine hydrochloride, lithium carbonate, doxycycline and sertraline hydrochloride, balofloxacin, and metformin, and gliclazide tablets; danazol, Lumbrokinase enteric-coated, and pseudoephedrine capsules; and simvastatin and epristeride piece, as well as injections of sodium sulfate prasterone. The company is based in Yangzhou, China.

jiangsu lianhuan pharmaceu-a (600513) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jiangsu lianhuan pharmaceu-a (600513) Key Developments

Jiangsu Lianhuan Pharmaceutical Co.,Ltd. Declares Dividend for the Year 2014; Approves Amendments to Articles of Association

Jiangsu Lianhuan Pharmaceutical Co.,Ltd. approved cash dividend (tax included) of CNY 0.85000000 per 10 shares for the year 2014, at the annual general meeting held on 18 March 2015. The company approved amendments to the company's articles of association.

Jiangsu Lianhuan Pharmaceutical Co.,Ltd. Proposes Amendments to Articles of Association

Jiangsu Lianhuan Pharmaceutical Co.,Ltd. proposed amendments to the company's articles of association at its 2014 Annual General Meeting to be held on March 18, 2015.

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year of 2014

Jiangsu Lianhuan Pharmaceutical Co. Ltd. reported earnings results for the full year of 2014. For the year, the company reported basic earnings per share of CNY 0.28 and weighted average return on net assets of 10.53%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600513:CH CNY19.92 CNY +0.35

600513 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600513.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600513 Industry Range
Price/Earnings 71.0x
Price/Sales 4.8x
Price/Book 7.2x
Price/Cash Flow 70.8x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JIANGSU LIANHUAN PHARMACEU-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at